Incidence and Clinical Features of PHACE Syndrome
Incidence, Risk Factor and Clinical Features of PHACE Syndrome
This study will include infants seen at three hospitals who have a segmental infantile hemangioma, a blood vessel growth affecting a broad area of skin. Eligible areas include the scalp, face, neck, upper chest or back, and shoulder or upper arm. The study will measure how often PHACE syndrome is found in infants with enough clinical information to determine the diagnosis. PHACE syndrome can involve differences in the development of the brain, arteries, heart, eyes, or the midline of the chest and abdomen. The study team will describe these findings and the hemangiomas. The treating clinicians will manage evaluation and care.
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
This prospective observational cohort will consecutively invite infants with a clinician-confirmed segmental cutaneous infantile hemangioma involving the head (including the scalp and face), neck, upper trunk, or proximal upper extremity at their first qualifying presentation to a participating center. Infants can enroll regardless of whether a PHACE evaluation or diagnosis is already documented. Prior evaluation and referral source will be recorded. Each infant will be enrolled once. A parent or legal guardian will provide written informed consent.
At enrollment, study clinicians will record age, sex, the anatomic distribution and laterality of the segmental lesions, the longest diameter of the largest qualifying lesion, and lesion depth. Photographs will be recorded when permitted by the protocol and consent. Each infant will be assigned to one anatomic stratum. The strata are head involvement with or without other sites, isolated neck, isolated upper trunk, isolated proximal upper extremity, and multiple sites without head involvement. All involved regions will also be recorded.
The study will collect clinical findings and results of clinically indicated assessments, including examination for ocular and ventral midline abnormalities, echocardiography, and magnetic resonance imaging and angiography of the head and neck, with aortic arch assessment. The treating team will determine which examinations and treatments are clinically appropriate. Prior assessments can contribute to classification when they meet the same protocol criteria for adequacy.
A central panel will apply the revised 2016 PHACE consensus diagnostic criteria. A hemangioma of the head, including the scalp, that exceeds 5 cm in diameter supports a diagnosis of definite PHACE when accompanied by at least one major or two minor criteria. For large segmental hemangiomas of the neck, upper trunk, or trunk with proximal upper-extremity involvement, definite PHACE requires at least two major criteria. Isolated proximal upper-extremity lesions will be described separately. Classification as definite PHACE will require documented fulfillment of the consensus criteria.
The primary analysis will include infants with a protocol-defined evaluable assessment by six months after enrollment. An evaluable assessment requires interpretable documentation of the prespecified core clinical, cardiac, and neurovascular evaluations, irrespective of the diagnostic classification. Definite PHACE, possible PHACE, and neither category will be reported separately. Inadequate evaluations will be recorded with the reason and retained in the enrollment count. The study will report the assessment completion proportion and the definite PHACE proportion with 95% confidence intervals overall and by anatomic stratum where estimable.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Yi Ji Ji, PhD
- Phone Number: 02885423453
- Email: jijiyuanyuan@163.com
Study Locations
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 610041
- Recruiting
- Children's Hospital of Fudan University
-
Contact:
- Zuopeng Wang Wang, PhD
- Phone Number: 028854223
- Email: 1192207223@qq.com
-
-
Sichuan
-
Chengdu, Sichuan, China
- Recruiting
- West China Hospital of Sichuan University
-
Contact:
- Yi Ji Ji, PhD
- Phone Number: 02885423453
- Email: jijiyuanyuan@163.com
-
Chengdu, Sichuan, China
- Recruiting
- West China Second Hospital of Sichuan University
-
Contact:
- Hu Fan Hu, PhD
- Phone Number: 02885423452
- Email: 1901613702@qq.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Infants from birth through 12 months of age at their first qualifying presentation during the recruitment period at one of the three participating centers, with a segmental cutaneous infantile hemangioma involving the head (including the scalp and face), neck, upper trunk, or proximal upper extremity.
Description
Inclusion Criteria
- From birth through 12 months of chronological age at enrollment.
- Clinician-confirmed segmental cutaneous infantile hemangioma involving the head (including the scalp and face), neck, upper trunk, or proximal upper extremity.
- First qualifying presentation at a participating center during the recruitment period.
- Written informed consent from a parent or legal guardian.
Exclusion Criteria
- The lesion responsible for eligibility is subsequently adjudicated to be a different vascular anomaly, such as a congenital hemangioma or vascular malformation.
- Prior enrollment in this study at any participating center.
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Infants With Segmental Infantile Hemangiomas
Infants with a segmental cutaneous infantile hemangioma involving the head (including the scalp and face), neck, upper trunk, or proximal upper extremity who are enrolled at one of the three participating centers. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of Evaluable Infants With PHACE Syndrome
Time Frame: At enrollment through 6 months after enrollment.
|
Percentage of infants with an evaluable PHACE assessment who fulfill the revised 2016 consensus criteria for PHACE. Evaluable assessments have the prespecified core clinical, cardiac, and neurovascular evaluations documented and interpretable. Each infant is counted once. |
At enrollment through 6 months after enrollment.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Anatomic Distribution and Laterality of Segmental Hemangiomas
Time Frame: At enrollment.
|
Number and percentage of infants by involved anatomic region and lesion laterality (left, right, bilateral, or midline) among infants with evaluable lesion documentation. |
At enrollment.
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
General Publications
- Haggstrom AN, Garzon MC, Baselga E, Chamlin SL, Frieden IJ, Holland K, Maguiness S, Mancini AJ, McCuaig C, Metry DW, Morel K, Powell J, Perkins SM, Siegel D, Drolet BA. Risk for PHACE syndrome in infants with large facial hemangiomas. Pediatrics. 2010 Aug;126(2):e418-26. doi: 10.1542/peds.2009-3166. Epub 2010 Jul 19.
- Garzon MC, Epstein LG, Heyer GL, Frommelt PC, Orbach DB, Baylis AL, Blei F, Burrows PE, Chamlin SL, Chun RH, Hess CP, Joachim S, Johnson K, Kim W, Liang MG, Maheshwari M, McCoy GN, Metry DW, Monrad PA, Pope E, Powell J, Shwayder TA, Siegel DH, Tollefson MM, Vadivelu S, Lew SM, Frieden IJ, Drolet BA. PHACE Syndrome: Consensus-Derived Diagnosis and Care Recommendations. J Pediatr. 2016 Nov;178:24-33.e2. doi: 10.1016/j.jpeds.2016.07.054. Epub 2016 Sep 19. No abstract available.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 20220212
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.